ERBB2 and breast carcinoma: It is plausible that the known alternative pathways for growth, such as the epidermal growth factor receptor and PI3K/AKT/mTOR pathways, are responsible for the association between poor prognoses and high parity in luminal B-like (HER2 negative) subtype breast cancers (26).